CancerDrs

Prostate Cancer clinical trials

300 actively recruiting prostate cancer trials in the United States. The most common cancer in men in the U.S. Trials test hormonal, radiation, surgical, and novel therapies across risk groups.

Data from ClinicalTrials.gov · last refreshed · Prostate Cancer stats on SEER

46
Phase 1
103
Phase 2
24
Phase 3
8
Phase 4
119
Other

Prostate Cancer by the numbers (U.S.)

313,780
Estimated new cases (2025)
35,770
Estimated deaths (2025)
97.9%
5-year relative survival
68
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse prostate cancer trials by state

California 99 New York 87 Texas 75 Florida 69 Maryland 48 Ohio 48 Pennsylvania 48 Michigan 45 Illinois 42 Massachusetts 42 Minnesota 38 Washington 38 Virginia 36 Tennessee 35 Wisconsin 33 Missouri 30 Oregon 30 South Carolina 30 Colorado 29 North Carolina 29 Arizona 27 Georgia 24 Nebraska 24 New Jersey 23 Connecticut 22 Oklahoma 20 Kentucky 17 Louisiana 16 Utah 16 District of Columbia 15 Indiana 15 Kansas 13 Iowa 11 Montana 10 Rhode Island 10 Arkansas 9 Idaho 9 Alabama 7 Delaware 7 Mississippi 7 South Dakota 7 Alaska 6 Nevada 6 New Hampshire 6 Wyoming 6 North Dakota 5 West Virginia 4 Maine 3 New Mexico 3 Hawaii 2 Vermont 2

Top trials by phase + site coverage

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Locations:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska
  • Alaska Oncology and Hematology LLC — Anchorage, Alaska

+ 319 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Locations:
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Alaska Breast Care and Surgery LLC — Anchorage, Alaska
  • Alaska Oncology and Hematology LLC — Anchorage, Alaska

+ 300 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Locations:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • Kaiser Permanente Dublin — Dublin, California

+ 183 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Locations:
  • Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
  • Highlands Oncology Group - Rogers — Rogers, Arkansas
  • Highlands Oncology Group — Springdale, Arkansas

+ 171 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Locations:
  • The University of Arizona Cancer Center - North Campus ( Site 0073) — Tucson, Arizona
  • UCLA Hematology/Oncology - Santa Monica ( Site 0044) — Los Angeles, California
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California

+ 56 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Vitamin D for Prostate Endocrine Therapy

This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…

Sponsor: University of Rochester
NCT ID: NCT05838716
Locations:
  • Helen F Graham Cancer Center — Newark, Delaware
  • Medical Oncology Hematology Consultants PA — Newark, Delaware
  • Carle at The Riverfront — Danville, Illinois

+ 48 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Sponsor: Pfizer
NCT ID: NCT06629779
Locations:
  • Ironwood Cancer & Research Centers — Chandler, Arizona
  • Ironwood Cancer & Research Centers — Gilbert, Arizona
  • Palo Verde Hematology Oncology — Glendale, Arizona

+ 41 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Locations:
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
  • Stanford Cancer Center ( Site 0036) — Palo Alto, California
  • Kaiser Permanente Riverside Medical Center ( Site 0099) — Riverside, California

+ 41 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Sponsor: Curium US LLC
NCT ID: NCT06235151
Locations:
  • Arkansas Urology — Little Rock, Arkansas
  • Providence Medical Foundation — Fullerton, California
  • Tower Urology — Los Angeles, California

+ 40 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Locations:
  • Arizona Clinical Trials — Chandler, Arizona
  • Arkansas Urology — Little Rock, Arkansas
  • University Of California San Diego — La Jolla, California

+ 29 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Sponsor: Amgen
NCT ID: NCT07213674
Locations:
  • City of Hope Cancer Center Phoenix — Goodyear, Arizona
  • City of Hope National Medical Center — Duarte, California
  • City of Hope Orange County Lennar Foundation Cancer Center — Duarte, California

+ 22 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Locations:
  • University of Alabama Birmingham Hospital — Birmingham, Alabama
  • Mayo Clinic- Phoenix — Phoenix, Arizona
  • Urology Group of Southern California — Los Angeles, California

+ 21 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

How to read clinical trial eligibility →

Inclusion, exclusion, biomarker requirements, performance status, and prior-therapy rules.

 How to find a clinical trial →

Search strategy, matching services, and when to involve your oncologist.

 Clinical trial phases explained →

Phase 1 through 4, what each means for patients.

 Insurance coverage for clinical trials →

The ACA requires coverage of routine patient costs. How to appeal denials.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-11